Suchergebnisse - "Synnott, Patricia G"

PubPharm (10)

1

enthalten in: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research | 2019

von Zimmermann, M. | Lubinga, S. | Banken, R. | +6

CommentOn: Value Health. 2019 Feb;22(2):161-167. - PMID 30711060

2

The Effectiveness and Value of Biologic Therapies for the Treatment of Uncontrolled Asthma

enthalten in: Journal of managed care & specialty pharmacy | 2019

von Tice, J. | Campbell, J. | Synnott, P. | +6

3

Impact of Abuse Deterrent Formulations of Opioids in Patients With Chronic Pain in the United States : A Cost-Effectiveness Model

enthalten in: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research | 2019

von Kumar, V. | Agboola, F. | Synnott, P. | +5

4

Cost Utility of Voretigene Neparvovec for Biallelic RPE65-Mediated Inherited Retinal Disease

enthalten in: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research | 2019

von Zimmermann, M. | Lubinga, S. | Banken, R. | +6

CommentIn: Value Health. 2019 Aug;22(8):970-971. - PMID 31426938

5

Assessing the Value of Sarilumab Monotherapy for Adults with Moderately to Severely Active Rheumatoid Arthritis : A Cost-Effectiveness Analysis

enthalten in: Journal of managed care & specialty pharmacy | 2019

von Whittington, M. | McQueen, R. | Ollendorf, D. | +5

ErratumIn: J Manag Care Spec Pharm. 2019 Jun;25(6):726. - PMID 31134862

6

The Authors Respond : Reframing the Value of Treatments for Relapsed Refractory Multiple Myeloma

enthalten in: Journal of managed care & specialty pharmacy | 2018

von Carlson, J. | Guzauskas, G. | Chapman, R. | +6

CommentOn: J Manag Care Spec Pharm. 2018 Jan;24(1):29-38. - PMID 29290170

7

Cost-effectiveness of Drugs to Treat Relapsed/Refractory Multiple Myeloma in the United States

enthalten in: Journal of managed care & specialty pharmacy | 2018

von Carlson, J. | Guzauskas, G. | Chapman, R. | +6

CommentIn: J Manag Care Spec Pharm. 2018 Jul;24(7):712-713. - PMID 29952702

8

Evaluating the Importance of Heterogeneity of Treatment Effect : Variation in Patient Utilities Can Influence Choice of the "Optimal" Oral Anticoagulant for Atrial Fibrillation

enthalten in: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research | 2016

von Cameron, C. | Synnott, P. | Pearson, S. | +3

9

Evaluating the Importance of Heterogeneity of Treatment Effect: Variation in Patient Utilities Can Influence Choice of the “Optimal” Oral Anticoagulant for Atrial Fibrillation

enthalten in: Value in health | 2016

von Cameron, C. | Synnott, P. | Pearson, S. | +3

10

Evaluating the Importance of Heterogeneity of Treatment Effect: Variation in Patient Utilities Can Influence Choice of the "Optimal" Oral Anticoagulant for Atrial Fibrillation

enthalten in: Value in health | 2016

von Cameron, C. | Synnott, P. | Pearson, S. | +3

1
[1]